VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs operating margin
Operating margin is operating income as a percentage of revenue.
VivoSim Labs's operating margin for the twelve months ending Jun 30, 2026 was -10117.0%. For fiscal 2026 it was -8768.7%, against -8761.1% the year before. The highest annual figure on record is -195.4% in fiscal 2010.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -8768.7% | −7.6 |
| FY2025 | Mar 31, 2025 | -8761.1% | +5079.3 |
| FY2024 | Mar 31, 2024 | -13840.4% | −9048.2 |
| FY2023 | Mar 31, 2023 | -4792.2% | −4026.9 |
| FY2022 | Mar 31, 2022 | -765.3% | +212.6 |
| FY2020 | Mar 31, 2020 | -977.9% | −95.5 |
| FY2019 | Mar 31, 2019 | -882.4% | −116.1 |
| FY2018 | Mar 31, 2018 | -766.3% | +145.7 |
| FY2017 | Mar 31, 2017 | -911.9% | +1693.8 |
| FY2016 | Mar 31, 2016 | -2605.7% | +2700.2 |
| FY2015 | Mar 31, 2015 | -5306.0% | −4527.4 |
| FY2012 | Dec 31, 2012 | -778.5% | −540.7 |
| FY2011 | Dec 31, 2011 | -237.9% | −42.5 |
| FY2010 | Dec 31, 2010 | -195.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -15327.8% | −7449.4 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -7967.5% | −1783.2 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -10576.9% | +3873.1 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -9410.7% | −717.4 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -7878.4% | +803.7 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -6184.3% | +4491.5 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -14450.0% | +59150.0 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -8693.3% | −3100.0 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -8682.1% | −3880.2 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -10675.9% | −8111.7 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -73600.0% | −69244.2 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -5593.3% | −5465.8 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -4801.9% | −3045.5 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -2564.1% | −2009.1 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -4355.8% | −3379.6 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -127.5% | +925.7 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -1756.4% | −918.6 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -555.0% | +82.2 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -976.2% | +123.5 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -1053.2% | −367.0 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -837.7% | −151.8 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -637.2% | +69.7 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -1099.7% | −69.4 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -686.2% | +630.0 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -685.9% | +150.8 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -706.9% | −18.1 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -1030.3% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -1316.3% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -836.8% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -688.9% | – |
See a number that looks wrong?